# Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

> **NCT03515044** · PHASE2 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 71 (actual)

## Conditions studied

- Overt Hepatic Encephalopathy

## Interventions

- **DRUG:** 40 mg Rifaximin SSD once daily
- **DRUG:** 40 mg Rifaximin SSD twice daily
- **DRUG:** 80 mg Rifaximin SSD once daily
- **DRUG:** 80 mg Rifaximin SSD twice daily
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03515044
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-13
- **Primary completion:** 2020-03-12
- **Final completion:** 2020-03-12
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03515044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03515044, "Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03515044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*